Cargando…
Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates
Tenofovir alafenamide fumarate (TAF) is the newest prodrug of tenofovir that constitutes several drug products used for the treatment of HIV/AIDS. Although the solid-state properties of its predecessor tenofovir disoproxil fumarate have been investigated and described in the literature, there are no...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238255/ https://www.ncbi.nlm.nih.gov/pubmed/32290280 http://dx.doi.org/10.3390/pharmaceutics12040342 |
_version_ | 1783536503949885440 |
---|---|
author | Lengauer, Hannes Makuc, Damjan Šterk, Damjan Perdih, Franc Pichler, Arthur Trdan Lušin, Tina Plavec, Janez Časar, Zdenko |
author_facet | Lengauer, Hannes Makuc, Damjan Šterk, Damjan Perdih, Franc Pichler, Arthur Trdan Lušin, Tina Plavec, Janez Časar, Zdenko |
author_sort | Lengauer, Hannes |
collection | PubMed |
description | Tenofovir alafenamide fumarate (TAF) is the newest prodrug of tenofovir that constitutes several drug products used for the treatment of HIV/AIDS. Although the solid-state properties of its predecessor tenofovir disoproxil fumarate have been investigated and described in the literature, there are no data in the scientific literature on the solid state properties of TAF. In our report, we describe the preparation of two novel polymorphs II and III of tenofovir alafenamide monofumarate (TA MF2 and TA MF3). The solid-state structure of these compounds was investigated in parallel to the previously known tenofovir alafenamide monofumarate form I (TA MF1) and tenofovir alafenamide hemifumarate (TA HF). Interestingly, the single-crystal X-ray diffraction of TA HF revealed that this derivative exists as a co-crystal form. In addition, we prepared a crystalline tenofovir alafenamide free base (TA) and its hydrochloride salt (TA HCl), which enabled us to determine the structure of TA MF derivatives using (15)N-ssNMR ((15)N-solid state nuclear magnetic resonance). Surprisingly, we observed that TA MF1 exists as a mixed ionization state complex or pure salt, while TA MF2 and TA MF3 can be obtained as pure co-crystal forms. |
format | Online Article Text |
id | pubmed-7238255 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72382552020-06-02 Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates Lengauer, Hannes Makuc, Damjan Šterk, Damjan Perdih, Franc Pichler, Arthur Trdan Lušin, Tina Plavec, Janez Časar, Zdenko Pharmaceutics Article Tenofovir alafenamide fumarate (TAF) is the newest prodrug of tenofovir that constitutes several drug products used for the treatment of HIV/AIDS. Although the solid-state properties of its predecessor tenofovir disoproxil fumarate have been investigated and described in the literature, there are no data in the scientific literature on the solid state properties of TAF. In our report, we describe the preparation of two novel polymorphs II and III of tenofovir alafenamide monofumarate (TA MF2 and TA MF3). The solid-state structure of these compounds was investigated in parallel to the previously known tenofovir alafenamide monofumarate form I (TA MF1) and tenofovir alafenamide hemifumarate (TA HF). Interestingly, the single-crystal X-ray diffraction of TA HF revealed that this derivative exists as a co-crystal form. In addition, we prepared a crystalline tenofovir alafenamide free base (TA) and its hydrochloride salt (TA HCl), which enabled us to determine the structure of TA MF derivatives using (15)N-ssNMR ((15)N-solid state nuclear magnetic resonance). Surprisingly, we observed that TA MF1 exists as a mixed ionization state complex or pure salt, while TA MF2 and TA MF3 can be obtained as pure co-crystal forms. MDPI 2020-04-10 /pmc/articles/PMC7238255/ /pubmed/32290280 http://dx.doi.org/10.3390/pharmaceutics12040342 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lengauer, Hannes Makuc, Damjan Šterk, Damjan Perdih, Franc Pichler, Arthur Trdan Lušin, Tina Plavec, Janez Časar, Zdenko Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates |
title | Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates |
title_full | Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates |
title_fullStr | Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates |
title_full_unstemmed | Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates |
title_short | Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates |
title_sort | co-crystals, salts or mixtures of both? the case of tenofovir alafenamide fumarates |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238255/ https://www.ncbi.nlm.nih.gov/pubmed/32290280 http://dx.doi.org/10.3390/pharmaceutics12040342 |
work_keys_str_mv | AT lengauerhannes cocrystalssaltsormixturesofboththecaseoftenofoviralafenamidefumarates AT makucdamjan cocrystalssaltsormixturesofboththecaseoftenofoviralafenamidefumarates AT sterkdamjan cocrystalssaltsormixturesofboththecaseoftenofoviralafenamidefumarates AT perdihfranc cocrystalssaltsormixturesofboththecaseoftenofoviralafenamidefumarates AT pichlerarthur cocrystalssaltsormixturesofboththecaseoftenofoviralafenamidefumarates AT trdanlusintina cocrystalssaltsormixturesofboththecaseoftenofoviralafenamidefumarates AT plavecjanez cocrystalssaltsormixturesofboththecaseoftenofoviralafenamidefumarates AT casarzdenko cocrystalssaltsormixturesofboththecaseoftenofoviralafenamidefumarates |